Loading viewer...
earnings
Format: PDF earnings
Fortrea reported Q2 2024 financial results, highlighting solid demand with increased RFP values from large pharma and biotech clients. The company doubled adjusted EBITDA versus Q1, progressed on cost reduction initiatives by exiting 60% of transition services, and divested non-core businesses while repaying $504M in debt. Key wins across top pharma and biotech companies were offset by missed book-to-bill targets due to slower biotech decision cycles.
earnings
10 Pages
Bioventus
iRhythm Technologies Q3 2023 Earnings Results
earningsearnings
15 Pages
iRhythm Technologies
Mayne Pharma Group FY23 Results 2023
earningsearnings
26 Pages
Mayne Pharma Group Limited